These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 17722485)

  • 1. Development of parallel line analysis criteria for recombinant adenovirus potency assay and definition of a unit of potency.
    Ogawa Y; Fawaz F; Reyes C; Lai J; Pungor E
    PDA J Pharm Sci Technol; 2007; 61(3):183-93. PubMed ID: 17722485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A potency assay for a replication incompetent adenovirus type 5 carrying a human fgf-4 gene.
    Fawaz FS; Elsheikh MA; Ogawa Y; Files JG; McCaman MT; Pungor E
    Anal Biochem; 2005 Jul; 342(1):34-44. PubMed ID: 15958178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of a statistical outlier in potency bioassays.
    Sondag P; Zeng L; Yu B; Rousseau R; Boulanger B; Yang H; Novick S
    Pharm Stat; 2018 Nov; 17(6):701-709. PubMed ID: 30112804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel Lack-of-Fit Assessment as a System Suitability Test for Potency Assays.
    Li R; Cai W; Zocher M
    PDA J Pharm Sci Technol; 2017; 71(5):368-378. PubMed ID: 28624777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of multivariate parallel-line bioassay with composite responses and composite doses, using canonical correlations.
    Yuan W; Kshirsagar AM
    J Biopharm Stat; 1993 Mar; 3(1):57-71. PubMed ID: 8485536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of the four-parameter logistic model to bioassay: comparison with slope ratio and parallel line models.
    Vølund A
    Biometrics; 1978 Sep; 34(3):357-65. PubMed ID: 719119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of bioassays for quality control.
    Lansky D
    Dev Biol Stand; 1999; 97():157-68. PubMed ID: 10463541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using QPCR to assign infectious potencies to adenovirus based vaccines and vectors for gene therapy: toward a universal method for the facile quantitation of virus and vector potency.
    Wang F; Puddy AC; Mathis BC; Montalvo AG; Louis AA; McMackin JL; Xu J; Zhang Y; Tan CY; Schofield TL; Wolf JJ; Lewis JA
    Vaccine; 2005 Aug; 23(36):4500-8. PubMed ID: 16002190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparisons of outlier tests for potency bioassays.
    Sondag P; Zeng L; Yu B; Yang H; Novick S
    Pharm Stat; 2020 May; 19(3):230-242. PubMed ID: 31762118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measuring parallelism, linearity, and relative potency in bioassay and immunoassay data.
    Gottschalk PG; Dunn JR
    J Biopharm Stat; 2005; 15(3):437-63. PubMed ID: 15920890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of an in vitro potency assay for therapeutic TGFbeta antagonists: the A549 cell bioassay.
    Rapoza ML; Fu D; Sendak RA
    J Immunol Methods; 2006 Oct; 316(1-2):18-26. PubMed ID: 17010369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A replication-competent adenovirus assay for E1-deleted Ad35 vectors produced in PER.C6 cells.
    Marzio G; Kerkvliet E; Bogaards JA; Koelewijn S; De Groot A; Gijsbers L; Weverling GJ; Vogels R; Havenga M; Custers J; Pau MG; Guichoux JY; Lewis J; Goudsmit J
    Vaccine; 2007 Mar; 25(12):2228-37. PubMed ID: 17250936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A personal computer-based system for parallel line analysis of bioassay data.
    Iznaga N; Núñez G; Solozabal J; Morales A; Artaza E; Rubio R; Cardenas E
    Comput Methods Programs Biomed; 1995 Jul; 47(2):167-75. PubMed ID: 7587163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of parallel line bioassay method to the potency test of anti-HBs immunoglobulin.
    Yasuda J; Saito H; Ishida S; Kurokawa M
    Dev Biol Stand; 1979; 44():129-38. PubMed ID: 544289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Multivariate twin crossover design parallel line assay for estimating potency of insulin].
    Lin ZG; Zhou HJ
    Zhongguo Yao Li Xue Bao; 1989 Nov; 10(6):565-8. PubMed ID: 2701785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Testing for parallelism in the heteroscedastic four-parameter logistic model.
    Sidik K; Jonkman JN
    J Biopharm Stat; 2016; 26(2):250-68. PubMed ID: 25629201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of experiment in assessing robustness and for qualification of a cell-based potency assay.
    Wilson R
    Bioanalysis; 2018 May; 10(10):737-746. PubMed ID: 29771136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statistical aspects of design and validation of microtitre-plate-based linear and non-linear parallel in vitro bioassays.
    Zimmermann H; Gerhard D; Dingermann T; Hothorn LA
    Biotechnol J; 2010 Jan; 5(1):62-74. PubMed ID: 19844917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A single short stretch of homology between adenoviral vector and packaging cell line can give rise to cytopathic effect-inducing, helper-dependent E1-positive particles.
    Murakami P; Pungor E; Files J; Do L; van Rijnsoever R; Vogels R; Bout A; McCaman M
    Hum Gene Ther; 2002 May; 13(8):909-20. PubMed ID: 12031124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A receptor-binding-based bioassay to determine the potency of a plasmid biopharmaceutical encoding VEGF-C.
    Waerner T; Girsch T; Varga S; Huang L; Gornikiewicz A; Loeber G
    Anal Bioanal Chem; 2007 Dec; 389(7-8):2109-13. PubMed ID: 17957358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.